Drug Registration in the Philippines: Why the Licence and the Product Are Two Separate Tracks

Who regulates medicines, and where the FDA stops

Human medicines fall under the Food and Drug Administration of the Philippines, an agency of the Department of Health, and specifically its Center for Drug Regulation and Research. The FDA answers two questions: who is eligible to import, wholesale, manufacture or distribute medicines, and whether a given product may be placed on the market.

The chain involves more than one authority, and exporters routinely underestimate the others:

• FDA drug centre. Issues the establishment licence and the product registration, reviews technical dossiers, approves labelling artwork and advertising material, and runs post-market sampling, pharmacovigilance and recalls. This is the office most applicants actually deal with.
• The drug enforcement authority (PDEA). Handles dangerous drugs and controlled precursor chemicals. If any ingredient sits on the schedules under the Comprehensive Dangerous Drugs Act, a separate licence and transaction-level authorisation are required on top of everything the FDA asks for, along with heavier obligations on premises security, custody by named personnel, and inventory records.
• The Bureau of Customs. At the port, customs checks that the importer holds the right accreditation and that FDA-side release documents exist. Customs does not evaluate your product; it checks whether the paperwork that should exist does exist.
• Professional and retail oversight. Pharmacists are licensed by the professional regulator, and the retail end is supervised jointly by the FDA and the local government unit. Operating a pharmacy is a different structure altogether, covered in the double-licence model behind a Philippine drugstore.

Before assembling anything, settle one classification question: is your product a medicine or a food supplement? The line runs through composition, dose form and claims. Anything that treats, prevents or diagnoses a disease, or that carries a pharmacologically active ingredient at a therapeutic dose, is handled as a medicine. Products limited to nutritional support go down the food route instead, described in supplement registration and the claim boundaries that trip exporters up. Getting this wrong usually means rejection at intake and a full restart, with earlier testing spend written off. For the wider map of which goods need permits at all, start with regulated and restricted imports in the Philippines.

Who is legally the importer and the registration holder

This is the single most consequential point on the page. A foreign pharmaceutical manufacturer cannot hold a Philippine License to Operate and cannot be the holder of a Certificate of Product Registration. The importer of record and the registration holder must be an entity incorporated in the Philippines with real premises that pass an FDA inspection. Your factory appears in the dossier as the overseas manufacturer, which is a different role from licence holder.

That leaves three routes, each with a real cost:

• Incorporate and hold the licence yourself. Set up a subsidiary or branch, obtain the LTO in your own name, hold your own registrations. Maximum control, registrations stay with you, and changing distributors later does not disturb market access. The trade-off is incorporation, premises, staffing and ongoing compliance, plus the longest lead time.
• Appoint an exclusive importer or distributor who holds it. Fastest to start because the licence already exists. But the registration sits in their name, and switching partners later often means repeating registration and sometimes retesting, which weakens your bargaining position at exactly the wrong moment.
• Engage a licensed third-party holder. A middle path where a specialist entity holds and maintains the file for you. Everything then depends on how the contract is drafted.

Whichever route you take, three clauses must be settled before signing: ownership and transferability of the registration, handover obligations and a cooperation period on termination, and the exclusivity and duration of the letter of authorisation. Most disputes in this sector are not about product quality; they are about a registration that cannot be recovered after a partnership ends.

One more warning. The workaround familiar from cross-border e-commerce does not exist here. Ordinary consumer goods can be declared through an importer-of-record service, but for FDA-regulated health products the importing party must itself be the licence holder, and no agency arrangement solves that. Customs-side importer accreditation is a separate layer, covered in how to obtain BOC and BIR importer accreditation. The same architecture recurs across every heavily regulated category: veterinary medicines and pet food are licensed by a different bureau under the agriculture department, and pesticides and fertilisers by the agricultural chemicals authority, yet the requirement for a local licensed holder is identical in all three.

Two parallel tracks: the establishment licence and the product dossier

The order is fixed: licence first, product second. The LTO establishes that an entity is fit to conduct the activity. The CPR establishes that a specific product may be marketed. They examine different things and their documentation barely overlaps.

The licence track is applied for by activity — importer, wholesaler or distributor, manufacturer, trader and so on. What you intend to do determines which category you need, and operating across categories generally means holding more than one. Review focuses on the entity and its premises: corporate documents, the physical warehouse (segregated storage, temperature and humidity control, cold chain where relevant, quarantine areas for returns and rejects), a documented quality system, and a qualified technical person, typically a registered pharmacist. The FDA inspects. Failing the warehouse inspection is one of the most common stalls. Licences expire and must be renewed; what happens when one lapses is set out in FDA licence renewal and the consequences of letting it lapse.

The product track is filed product by product, and the tiering runs along four axes: active ingredient, dosage form, strength, and manufacturing site. Change any one of them and you generally have a separate application rather than an annex to an existing one. This is the single most under-budgeted item in exporter planning. On top of that, products are tiered by nature: a new chemical entity versus a generic of an existing molecule, prescription versus over-the-counter, small molecule versus biologic or vaccine. The depth of technical evidence differs sharply between tiers.

Dossier format across the region has been harmonised as the ASEAN Common Technical Dossier, generally comprising administrative documents plus quality, non-clinical and clinical parts; generics carry their own expectations around bioequivalence. Overseas manufacturing sites are normally expected to produce a valid GMP certificate and a Certificate of Pharmaceutical Product from the competent authority in the exporting country, and the FDA may inspect a foreign plant. Biologics and vaccines may additionally face batch release requirements. Validity periods, fees and review timelines follow whatever the FDA currently publishes; no figures are given here.

Labelling, packaging and the advertising line you cannot cross

For medicines, labelling is not a packaging-design task. Artwork is part of the registration: it is reviewed with the dossier, and changing it afterwards without clearance is an unapproved variation.

The Philippines applies one rule that surprises most first-time exporters: the generic name must be displayed prominently. This flows from the policy established by the Generics Act, which requires the generic name to be presented in a prescribed manner, typically more conspicuously than or ahead of the brand name. Artwork translated directly from a home-market carton, with a large brand name and the generic name tucked into a corner, is a predictable rejection.

Beyond that, labelling and the package insert generally need to carry:

• generic and brand name, dosage form and strength;
• active ingredients and principal excipients;
• batch number, manufacturing date and expiry;
• the names and addresses of both the manufacturer and the local importer or distributor;
• the product registration number;
• storage conditions and pack size;
• prescription status, indications, dosage, contraindications, warnings and adverse reactions, usually carried on the insert;
• English text, and metric units throughout.

The general consumer-goods baseline is described in Philippine product labelling rules, but medicines sit above that baseline rather than within it.

Advertising is the more dangerous half. Two rules dominate. First, drug advertising generally requires clearance before publication, not after. Second, prescription medicines may not be advertised to the general public at all; promotion is confined to channels aimed at healthcare professionals. The most frequent failure in practice is treating paid social posts, influencer reviews, livestream scripts and marketplace product pages as content rather than advertising. Under the regulator's reading, all of it is commercial communication, all of it is regulated, and all of it can be named in a public advisory and pulled from platforms. Claims must also stay inside the approved indications, and consumer testimonials must not be used to imply efficacy. The workable discipline is simple: every outbound piece of copy is checked against the approved registration text before it goes live.

Arrival, release and post-market duties: can you ship first and register later?

The direct answer is no. Medicines are a heavily regulated health product, and the sequence is fixed: local entity obtains the LTO, each presentation obtains its CPR, import-stage release documentation is arranged under the rules in force, and only then is the shipment booked. Sending goods ahead and regularising on arrival has essentially no room to work in this category.

Where goods are already in transit or already at the port without complete documentation, consequences usually unfold in this shape:

• Detention. The consignment is not released and sits in a customs-controlled facility awaiting disposition, while storage and demurrage accrue daily at the consignee's expense.
• Re-export. Where permitted, the cargo may be returned or rerouted, with all freight and handling borne by the owner and cooperation required from the origin side to receive it.
• Destruction. Where nothing can be corrected and return is not possible, supervised destruction follows, again at the owner's cost.
• Knock-on effects. The importer's accreditation and future declarations may attract closer attention, raising inspection rates on later shipments.

General handling of a detained consignment is covered in what to do when customs holds your shipment, the economics of sending it back in re-export procedures and who pays, and the overall sequence in the Philippine import clearance process. Note what those routes do and do not solve: they address what happens to the cargo, not whether the product may be sold.

Release is the beginning, not the end. Ongoing obligations typically include market sampling and inspection; adverse-event reporting and pharmacovigilance; recall and cooperation with investigations when a quality issue emerges; and variation filings whenever something changes. Manufacturing site, formulation, strength, packaging material, artwork and the identity of the registration holder are all changes, usually split between major variations needing prior approval and minor ones requiring only notification. Misjudging that split can amount to selling an unregistered product. Renewal is the last recurring duty, is not a formality, generally requires quality and safety data from the current cycle, and runs inside a defined window. Exact periods follow current FDA issuances.

Eight recurring mistakes, and the limits of what Yixing does

Ranked roughly by how often they appear:

1. Misclassifying the product. Filing a medicine as a supplement, or the reverse. Active pharmaceutical ingredients or disease claims put you on the medicine track regardless of how the product is marketed at home.
2. Negotiating sales before securing a licence holder. Distribution is agreed, then the absence of a licensed local entity resets the entire timeline. The holder question should be decided first, not last.
3. Letting a partner hold the registration with no exit clause. Nobody minds while the relationship works; the problem only surfaces when it ends and the product is locked to the former partner.
4. Underestimating tiering. Three strengths means three applications. A new manufacturing site means starting again. Quote by presentation and site, not by brand.
5. Translating home-market artwork. A non-prominent generic name, missing importer details, missing registration number, non-metric units and absent warnings are perennial rejection grounds.
6. Treating paid social as content. Any public-facing promotion of a prescription medicine is a high-risk act.
7. Treating variations as trivial. Changing an excipient supplier, a packaging material or the local agent may all require prior approval.
8. Ignoring the second gate. If an ingredient is scheduled as a dangerous drug or controlled precursor, completing the FDA track finishes only half the work.

One structural misconception is worth naming separately: harmonised regional dossier format does not mean one approval covers the region. The common technical dossier standardises how you present evidence, not who decides. Each member state still reviews and issues its own approval.

What Yixing does, and what it does not. Yixing is a private consultancy with no affiliation to any government agency. Its credentials are SEC registration CS202009551, Bureau of Immigration Accreditation No. CA-202624381-1, Department of Labor and Employment accreditation, and Philippine Retirement Authority accreditation. Medicines are FDA-regulated health products, and on the establishment licence and product registration side Yixing can assist, including arranging registration through a licensed holder where you have no local company yet. The layer underneath is also ours: incorporating the local entity and structuring shareholding, work permits and visas for the technical and management staff you post here, importer accreditation, and administrative compliance once you are operating. That work sits under our product access services, and the overall two-step logic is outlined in the FDA registration overview.

Two limits, stated plainly. Medicines carry stricter, dedicated requirements than ordinary consumer health products — dossier depth, GMP and pharmaceutical product certification, pharmacist and premises conditions all sit above the food and cosmetics tier — and controlled substances run through a separate licensing gate at the drug enforcement authority, outside general product access. Laboratory testing, dangerous goods documentation and customs brokerage are likewise outside our scope. Whether a given molecule and dosage form is workable, and on what schedule, has to be assessed case by case, with a licensed pharmaceutical registration agent taking the filing where that is the right answer. Approval authority always rests with the regulator, and no firm can promise an outcome.

Finally: this is a general explanation of a regulatory framework, not advice on any specific product, and it is neither legal advice nor medical advice. For a specific case, consult a licensed attorney or an accredited pharmaceutical regulatory agent, and rely on the current issuances of the competent authority.